MedTrace Logo

Suicide Prevention for Sexual and Gender Minority Youth (Randomized Controlled Trial)

NCT05669976 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 170

Last updated 2026-05-07

No results posted yet for this study

Summary

The overarching goal of this study is to evaluate a newly-developed suicide prevention program for sexual and gender minority youth and emerging adults. After development of the intervention program, a randomized controlled trial will be conducted to test its preliminary efficacy in lowering the risk for suicide attempts.

Conditions

  • Suicide

Interventions

BEHAVIORAL

Safety Planning Intervention with Navigation Services

A patient navigation (PN) intervention for SGM youth/emerging adults designed to target mechanisms (i.e., decreasing thwarted belongingness and increasing suicide-related coping skills) that theoretically underlie suicide. The proposed intervention integrates a single-session, empirically supported, suicide prevention intervention (Safety Planning Intervention; SPI) with PN services (PN+SPI). The patient navigator will deliver the SPI and continue frequent contact for the purpose of providing motivational enhancement, problem-solving, reinforcing coping strategies, and connecting participants to mental health and social support resources (e.g., SGM-specific support groups within the community).

BEHAVIORAL

Safety Planning Intervention

The Safety Planning Intervention (SPI) is a single-session, empirically supported, suicide prevention intervention. The patient navigator will deliver the SPI.

Sponsors & Collaborators

  • National Institute of Mental Health (NIMH)

    collaborator NIH

  • San Diego State University

    lead OTHER

Principal Investigators

  • Aaron J Blashill, Ph.D. · San Diego State University

  • Kristen J Wells, Ph.D. · San Diego State University

  • Arjan van der Star, Ph.D. · San Diego State University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
15 Years
Max Age
29 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-04-10
Primary Completion
2027-05-05
Completion
2027-05-05

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05669976 on ClinicalTrials.gov